TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01239056

Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
Study: NCT01065337

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow stem cells (BMC)
Description: bone marrow stem cells
Study: NCT03695172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.
Study: NCT02172508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Inhalation Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lactose Capsule
Study: NCT02040532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
Study: NCT00464737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
Study: NCT03138356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet
Description: Used in Treatment B and Treatment E.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet
Description: Used in Treatment B and Treatment E.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet
Description: Used in Treatment A and Treatment D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet
Description: Used in Treatment A and Treatment D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg dapagliflozin / 850 mg metformin XR FDC
Description: Used in Treatment H.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg dapagliflozin / 1000 mg metformin XR FDC
Description: Used in Treatment G.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5 mg ONGLYZA® (saxagliptin) tablet
Description: Used in treatments C and F.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5 mg ONGLYZA® (saxagliptin) tablet
Description: Used in treatments C and F.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Forxiga® (dapagliflozin) tablet
Description: Used in treatments C, F and I.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Forxiga® (dapagliflozin) tablet
Description: Used in treatments C, F and I.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Forxiga® (dapagliflozin) tablet
Description: Used in treatments C, F and I.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg Glucophage XR®
Description: Used in treatments C, F and I.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg Glucophage XR®
Description: Used in treatments C, F and I.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg Glucophage XR®
Description: Used in treatments C, F and I.
Study: NCT02814279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF plus connective tissue graft
Description: Periodontal surgery for root coverage by the trapezoidal flap associated with connective tissue graft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel plus connective tissue graft
Description: Periodontal surgery for root coverage by the tunnel flap associated with connective tissue graft.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium dipyrone
Description: All participants were instructed to take 500 mg sodium dipyrone just in case of pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium dipyrone
Description: All participants were instructed to take 500 mg sodium dipyrone just in case of pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine rinse
Description: All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine rinse
Description: All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
Study: NCT02623686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma Therapy Massage and Inhalation Patch
Study: NCT01396733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha-lipoic acids
Description: alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha-lipoic acids
Description: alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
Study: NCT02674555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radio-labeled naquotinib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib
Description: Oral administration
Study: NCT02978846

Intervention type: OTHER
Intervention: Clinical Observation
Description: Undergo side effects evaluation using cards
Study: NCT00662883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMI-150 (intranasal ketamine HCl); mometasone furoate
Description: * 1 dose PMI-150 (intranasal ketamine HCl); day 1~* mometasone furoate, daily; days 2-15~* 1 dose PMI-150 (intranasal ketamine HCl); day 15
Study: NCT01064856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
Study: NCT02831751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 µg/strain of Quadrivalent VLP Vaccine
Description: Single dose of non-adjuvanted Quadrivalent VLP Vaccine
Study: NCT02212028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: the effects of whole tablets versus crushed tablets will be compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: the effects of whole tablets versus crushed tablets will be compared
Study: NCT00978601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal analgesic protocol during minimally invasive myomectomy
Description: Multimodal and preemptive analgesia using 8 mg of Dexamethasone iv,trocar ports infiltration with 5 mL of a local anesthetic, consisting of 0.26% ropivacaine HCL (7.5 mg/mL) and 0.74% of 0,9 % sodium chloride, before the skin incision. About 10 minutes before the surgery is completed, 4 mg Ondansetron iv and a mixture of 75 mg diclofenac and 600 mg of paracetamol intramuscularly (im) are administered.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Multimodal analgesic protocol during minimally invasive myomectomy
Description: Multimodal and preemptive analgesia using 8 mg of Dexamethasone iv,trocar ports infiltration with 5 mL of a local anesthetic, consisting of 0.26% ropivacaine HCL (7.5 mg/mL) and 0.74% of 0,9 % sodium chloride, before the skin incision. About 10 minutes before the surgery is completed, 4 mg Ondansetron iv and a mixture of 75 mg diclofenac and 600 mg of paracetamol intramuscularly (im) are administered.
Study: NCT03955601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''
Description: ''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment , ''ATG'' will be used to reduce GVHD and facilitate engraftment while ''combine PBSC'' and/OR ''Bone marrow harvest'' will be used
Study: NCT03667950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperspectral Imaging
Description: Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
Study: NCT00902304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan and hydrochlorothiazide (HCTZ) - monotherapy
Description: Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan and amlodipine
Description: From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
Study: NCT02413073

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Whole Body Vibration
Description: We wil use vibration in patients with kidney disease

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: We wil use vibration in patients with kidney disease
Study: NCT01104233

Intervention type: DEVICE
Intervention: LAP Protector
Description: The LAP Protector is a device that consists of two flexible rings made of superelasticity alloys covered with polyurethane polyamide, and a thin silicone rubber membrane that is attached to the outer rim of the two rings
Study: NCT03834584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-636
Description: AG-636 will be administered orally intermittently in 28-day cycles.
Study: NCT04482114

Intervention type: RADIATION
Group type: OTHER
Intervention: ULD CT
Description: All the examinations are part of the routine care. Addition of the ULD CT protocol does not require injection of contrast agent and does not extend the duration of the examination.
Study: NCT04657484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medium dose prednisolone
Description: Same as arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose prednisolone
Description: Same as arm description
Study: NCT01040221

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trichuris Suis Ova
Description: TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichuris Suis Ova
Description: TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
Study: NCT00638170

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice
Description: 5 ml/kg up to 300 ml, 1-2 doses daily for six months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: 5 ml/kg up to 300 ml, 1-2 doses daily for six months
Study: NCT02658409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3106(quadrivalent cell-culture based influenza vaccine)
Description: GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)
Description: Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
Study: NCT01682161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
Study: NCT01045499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (Allergan Lap Band)
Description: Pre-op evaluation, surgical placement of a gastric band, and follow-up for a minimum of 5 years after surgery. Surgery is laparoscopic adjustable gastric band placement using a single brand of gastric band. Evaluations before and after surgery include but are not limited to history and physical examination, serum chemistry studies, imaging, sleep studies, and pulmonary function testing.
Study: NCT02730065

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Aerobic Dance Training Group
Description: Systematic physical activity

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching plus education
Description: Weekly group based stretching with psychoeducation and health education
Study: NCT04749524

Intervention type: DIAGNOSTIC_TEST
Intervention: Medial-Olivocochlear Reflex (MOCR) Strength Measurement
Description: Otoacoustic emissions (OAE) will be recorded using an ear probe with and without an efferent Medial-Olivocochlear Reflex (MOCR) elicitor.

Intervention type: DIAGNOSTIC_TEST
Intervention: Medial-Olivocochlear Reflex (MOCR) Strength Measurement
Description: Otoacoustic emissions (OAE) will be recorded using an ear probe with and without an efferent Medial-Olivocochlear Reflex (MOCR) elicitor.

Intervention type: DIAGNOSTIC_TEST
Intervention: Medial-Olivocochlear Reflex (MOCR) Strength Measurement
Description: Otoacoustic emissions (OAE) will be recorded using an ear probe with and without an efferent Medial-Olivocochlear Reflex (MOCR) elicitor.

Intervention type: DIAGNOSTIC_TEST
Intervention: Medial-Olivocochlear Reflex (MOCR) Strength Measurement
Description: Otoacoustic emissions (OAE) will be recorded using an ear probe with and without an efferent Medial-Olivocochlear Reflex (MOCR) elicitor.
Study: NCT00472446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bilateral superficial cervical block
Description: 10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bilateral superficial cervical block
Description: 10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo bilateral superficial cervical block
Description: 10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo bilateral superficial cervical block
Description: 10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
Study: NCT00672828

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-tailored CRC screening brochure
Description: Patients receive written educational material about colorectal cancer and prompting to talk to their doctor about getting tested.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive computer intervention
Study: NCT03830047

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: nd yag laser
Description: nd yag laser will be applied on the vulval warts
Study: NCT04272944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg Q2W
Description: 10 mg/kg MSB2311 every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg/kg Q3W
Description: 20 mg/kg MSB2311 every three weeks.
Study: NCT02831751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg/strain of Quadrivalent VLP Vaccine
Description: Single dose of non-adjuvanted Quadrivalent VLP Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluLaval® Tetra (15 µg/strain)
Description: Single dose of a licensed quadrivalent vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® High-Dose (60 µg/strain)
Description: Single dose of a licensed trivalent vaccine
Study: NCT05079958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral education
Description: four-week cognitive-behavioral education course

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week brisk walking
Description: 12-week brisk walking
Study: NCT03771209

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound examination
Description: ultrasound assessment
Study: NCT00615355

Intervention type: RADIATION
Group type: OTHER
Intervention: UVB 311 nm radiation
Description: UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UVB 311 nm radiation
Description: UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVB 311nm
Description: Repeated UVB 311nm narrowband irradiation (24 exposures)
Study: NCT01283971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Adalimumab 40 mg SC every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to tocilizumab
Description: Placebo to tocilizumab IV every 4 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to adalimumab
Description: Placebo to adalimumab SC every 2 weeks for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Methotrexate 10-25 mg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate 10-25 mg weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folate
Description: Folate at least 5 mg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folate
Description: Folate at least 5 mg weekly.
Study: NCT02062671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: renal denervation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal denervation
Study: NCT02985255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Neoadjuvant Arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Neoadjuvant Arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: Neoadjuvant Arm

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Neoadjuvant Arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glossectomy
Description: Neoadjuvant Arm
Study: NCT00902304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: As directed by investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 160mg per day to 320mg per day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan and hydrochlorothiazide (HCTZ) - combination arm
Description: Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
Study: NCT03382561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV